Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Inclusion Criteria: * Original HCT donor: The most recent transplant was from a related or unrelated donor with an allele-level match to the recipient at HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 (10/10) or with a single antigen or allele mismatch (9/10), or with one or two umbilical cord blood units that are individually antigen-level matched to the recipient in at least 4 of 6 HLA loci (HLA-A, -B, -DRB1). * Graft source: The most recent transplant (and any previous allotransplant) was from mobilized peripheral blood stem cells and/or bone marrow and/or umbilical cord blood. * Transplant number: The relapse occurred after a 1st, 2nd or 3rd allogeneic HCT. * Diseases: The subject relapsed or progressed with the same or related disease which prompted the previous allogeneic HCT. * Leukemia (acute myeloid leukemia \[AML\], acute lymphoblastic leukemia \[ALL\], chronic myelogenous leukemia \[CML\], chronic lymphocytic leukemia \[CLL\], chronic myelomonocytic leukemia \[CMML\], blastic plasmacytoid dendritic cell, biphenotypic, bilineage) * Myelodysplasia * Myeloproliferative neoplasm * Myelodysplasia/myeloproliferative neoplasms (including "unclassified"). * For subjects with persistent or relapsed acute B-cell lymphoblastic leukemia, the subject must have previously received a chimeric antigen receptor (CAR) T cell product and blinatumomab at any point (not necessarily to treat the current relapse or after the current allogeneic transplant), unless the subject is inelig…